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Abstract
Gray platelet syndrome (GPS) is a predominantly recessive platelet disorder characterized by a
mild thrombocytopenia with large platelets and a paucity of α-granules; these abnormalities cause
mostly moderate but in rare cases severe bleeding. We sequenced the exomes of four unrelated
cases and identified as the causative gene NBEAL2, a gene with previously unknown function but
a member of a gene family involved in granule development. Silencing of nbeal2 in zebrafish
abrogated thrombocyte formation.
Platelets are the second most abundant cell in the blood and maintain arterial vessel wall
integrity. Formation of the platelet plug at the site of vessel wall damage is a multi-step
process of tethering and attachment followed by activation that causes the release of both the
α- and δ-granules. Platelets are anucleate and formed in large numbers in the bone marrow
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by polyploid precursor cells, named megakaryocytes (MKs). The lack of adequate numbers
or impaired function of platelets can result in bleeding. GPS was first defined in 1971 when
it was observed that in some cases with an inherited bleeding disorder a May-Grünwald-
Giemsa stained blood smear showed gray platelets with increased diameter1. Electron
microscopic studies revealed a complete lack of α-granules in most cases2 (Fig. 1a). Since
the α-granule protein cargo is essential to the development of a robust platelet plug, GPS
cases are symptomatic at platelet count levels that are typically not associated with bleeding.
Proteins normally only released upon platelet activation are spontaneously released from
MKs; most likely because of the lack of α-granules3.
A recent study established significant linkage of a locus on chromosome 3p21 to GPS, but
the causative gene has remained elusive so far4,5. We therefore sequenced the exomes of
four unrelated cases with GPS (Supplementary Table 1-2, Supplementary Fig. 1,
Supplementary Note), using the Agilent SureSelect protocol to enrich for 39.3 Mb of coding
sequence and the Illumina GAII platform6. GPS is an extremely rare disorder, illustrated by
the fact that there are about 30 documented cases in France; cases typically occur in families
consistent with a recessive disorder4. We hypothesized that the causative variants would be
novel, and filtered out variants seen previously and those not likely to affect protein function
(Online Methods). Assuming a recessive mode of inheritance we required at least two novel
mutations per individual in the same gene.
We found that only for the Neurobeachin-like 2 gene (NBEAL2), encoding a member of the
family of BEACH domain containing proteins, on chromosome 3 (3p21) all cases had at
least two novel mutations with a predicted functional consequence for the protein, with two
homozygous cases and two compound heterozygotes (Table 1, Fig. 1b). All mutations and
genotypes were confirmed by capillary sequencing (not shown). Based on theoretical
calculations we estimate that the probability of the observed mutation pattern occurring by
chance is ~5 × 10−11 (Supplementary Note). Furthermore, we established correct
segregation in a further five relatives, two unaffected and three affected ones, in pedigrees
A, B and C and identified the affected father (B.I.2) of case B.II.3 as homozygous for the
causative mutation, compatible with the known consanguinity in this pedigree
(Supplementary Note). The mutations were at eight different locations in the 2,754 amino
acid long Nbeal2 protein and were absent in 994 low-pass samples from the main phase of
the 1000 Genomes Project7. Except for mutation G2553E in case D.II.3, all affected residues
for the nsSNPs are highly conserved, as well as the splice site disrupted by the 7-base pair
insertion in the same case (Table 1, Supplementary Fig. 2-9). The eight mutations affect
multiple exons of NBEAL2 and multiple protein domains, with the P2100L and S2269L
variants being located in the BEACH domain itself. Modeling based on the fold of the
homologous PH-BEACH structure from NBEA8 (>50% identity at the amino acid level)
shows that the environment of the former mutation would introduce clashes in a tightly-
packed location of a hydrophobic pocket and the latter would potentially lead to local
changes in conformation (Supplementary Fig. 10).
To verify the biological importance we silenced the nbeal2 orthologous gene by injecting
specific antisense morpholino oligonucleotides (MO) into one cell stage zebrafish embryos
(Supplementary Fig. 11). This resulted in a lineage-specific effect with a complete
abrogation of thrombocyte formation, but normal erythropoiesis (Fig. 1c, d). Spontaneous
bleeding in the tail was observed in 41% of the embryos (Fig. 1e and Supplementary Fig.
11). The phenotype in MO-injected zebrafish is more severe than the observed phenotype of
GPS cases, which may be expected due to the difference between a null-phenotype in
zebrafish and a loss of function one in the GPS cases. Although the experiment did not
address the function of α-granules in thrombocytes, these results support the essential role
of the Nbeal2 protein in thrombopoiesis and the etiology of GPS.
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Other members of the family of BEACH domain proteins include Nbea, Nbeal1, Lrba and
Lyst (Supplementary Fig. 12) and are believed to be important in membrane protein
trafficking9. Like other BEACH members except for NBEAL1, NBEAL2 is expressed in
MKs and indeed is upregulated during megakaryopoiesis (Supplementary Fig. 13-14).
Mutations in other BEACH members affect vesicle function in both man and mice. Haplo-
insufficiency of the NBEA gene caused by a chromosomal rearrangement in an individual
with extreme autism was associated with atypical platelet δ-granules, suggestive of a
possible role of Nbea in their formation10, while the platelet α-granules were normal. In
contrast with Nbea, which in mouse is required for the formation and functioning of central
neuronal synapses11, NBEAL2 is not expressed in fetal and whole brain (Supplementary
Fig. 15), consistent with the lack of neurological phenotypes in cases with GPS. Mutations
in the LYST gene that result in the truncation of the BEACH/WD40 domains or the total
absence of the Lyst protein lead to a dysregulation of lysosomal trafficking and are causative
of Chediak-Higashi syndrome12, for which symptoms include a platelet-type bleeding due to
inadequate formation of δ-granules13. However, there was no previously known function for
NBEAL2 and it is has not been associated with common or rare disease, and is absent from
any of the 68 quantitative trait loci that were identified in a recent GWAS meta-analysis for
the number and volume of platelets in 68,000 healthy individuals (N. Soranzo, unpublished
data). Taken together, these findings are consistent with a role for Nbeal2 in the
development or secretion of platelet α-granules, whereby individuals with recessive
mutations have impaired platelet activation and plug formation, resulting in a propensity for
bleeding.
Our result is supported by the findings of two previous linkage studies. Gunay et al. found
that 19 affected individuals in 11 out of 14 pedigrees (one being case A.I.3 from this study)
analyzed in total were homozygous in the region chr3:42688625-52061914 on 3p21, which
contains NBEAL2, together with a significant linkage of log-odds (LOD) ratio of 7.2 in the
largest pedigree4. They sequenced 69% of all exons in the homozygous interval, but no gene
was identified. In a separate linkage study, Fabbro et al. reported a LOD score of 2.7 for the
same locus and subsequently identified four affected individuals from two pedigrees that
were completely homozygous and one individual that was mostly homozygous for the
region chr3:48487338-50187790, which does not include NBEAL25. Targeted next-
generation resequencing of this region did not identify a causative gene. Interestingly, the
segregation pattern inferred from microsatellite markers in the two pedigrees is consistent
with compound heterozygosity for an interval that does contain NBEAL2, and based on
mixed ethnicity in one pedigree the authors raised this as a possibility5.
In summary, we identified multiple novel mutations in NBEAL2, a gene with no previously
known function, in Gray Platelet Syndrome, a known recessive disorder. It is consistent with
an important role for Nbeal2 in the formation of α-granules and this discovery may lead to
the development of a novel generation of safer anti-platelet drugs for use in the treatment of
individuals with heart attacks and stroke. A comparison with two previous linkage studies
demonstrates the power of directly observing sequence variation for resolving complex
segregation patterns, in particular combinations of compound heterozygosity and
homozygosity.
Methods
Sequencing
We applied the Agilent SureSelect protocol (Agilent, South Queensferry, UK, catalogue no.
G3362A) to enrich for 39.3 Mb of sequence covering 740K exons in 79K transcripts from a
highly redundant set of 34,642 genes. The enriched DNA was sequenced on the Illumina
GAII platform (Illumina, Little Chesterford, UK). We generated 11.7-13.4 Gb of sequence
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per individual, resulting in a mean coverage of 103-112-fold and 88.3-92.3% of the sites
within 25 bp of the targets covered at least ten-fold.
Sequence analysis
The sequence analysis was divided into three phases with the first one consisting of aligning
and recalibrating the reads to produce a BAM file15. The second phase consisted of calling
the sequence variants using various algorithms. The third phase consisted of filtering the set
of variants.
First phase:
1. The FastQ files generated by the sequencing pipeline were aligned to reference
NCBI build 37 using the Stampy read mapper16.
2. For each lane independently, the reads were realigned around known insertions and
deletions (indels) (1000 Genomes pilot project,7), followed by base quality
recalibration using the Genome Analysis Toolkit (GATK)17.
3. After merging the different lanes, duplicates were flagged using the Picard software
package18 and excluded from subsequent analyses.
Second phase:
1. Indels were called using Dindel19 on each sample independently.
2. The reads were realigned in the BAM files produced in phase 1 around the indels
called by Dindel using the GATK, in order to reduce alignment artefacts around all
indels found in a sample.
3. The GATK software package and SAMtools were used to call Single Nucleotide
Polymorphisms (SNPs)15. We called SNPs both for each sample independently and
jointly using all samples. Furthermore, SNPs were called both from the BAM files
produced in phase 1 and in step 2 of the second phase, so that SNPs were called
using six different approaches. The joint calling was performed using exome
sequencing results of 32 additional DNA samples from individuals with unrelated
clinical phenotypes on the realigned BAM files produced in step 2 of the second
phase.
4. We required a minimum variant quality of 20, which corresponds to a 99%
confidence level. Furthermore, we removed variants with more than 10 reads with
mapping quality 0 as a proxy for regions in the genome where mappings are likely
unreliable.
Third phase:
1. Variants that did not overlap the targeted regions ±25 bp were filtered and not
considered in further analyses.
2. We predicted the functional consequence of SNPs and small indels using the
Ensembl Variation API20.
3. We considered only non-synonymous (ns) SNPs, SNPs introducing a premature
stop-codon, indels in protein coding sequence, and variants affecting 3′UTRs and
essential splice sites.
4. Each variation was annotated for presence in databases of genetic variation. Any
variant found to be present was not considered as a candidate for GPS. The
following public databases were used: dbSNP131, SNPs from 8 HapMap
exomes21, the 1000 Genomes pilot project SNPs and indels7. In addition to these
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public resources we made also use of the variation data observed in 354 exomes
from the CoLaus cohort, which have been sequenced at the Wellcome Trust Sanger
Institute as part of a partnership between the Sanger Institute, the CoLaus principal
investigators (P Vollenweider, Department of Internal Medicine, University
Hospital Center, University of Lausanne, Lausanne, Switzerland and
GlaxoSmithKline (GSK) (V Mooser, GSK, Philadelphia, USA)14. We also used as
a filter the variants called on 32 exomes sequenced on the same platform for
unrelated studies, which allowed us to correct for systematic errors in the variant
calling.
Statistical significance of observed mutations
We estimated the significance of the novel mutations identified in the four exome-sequenced
GPS cases using a dynamic programming approach based on the coalescent. The coalescent
is a mathematical description of the notion that ultimately all individuals are related through
a single common ancestor22.
Since the observed mutation pattern is extremely rare and generally would only expected to
be seen by conditioning on a rare event, for instance the presence of a rare phenotype,
permutation analyses would not provide an accurate estimate of the significance.
We therefore assume a population of Na chromosomes of affected individuals, and Nu
chromosomes of unaffected individuals. The infinite site model provides an estimate of the
number of variable sites in genomic segment of length L through the population-scaled
mutation rate θ. The relationship θ = 4Neμ, relates the population scaled mutation rate to
Ne, the effective population size, and μ, the per-generation mutation rate. Here, we assumed
an effective population size of 23000, which is based on the mutation rate μ=1.1 × 10−8
estimated from trios7 and a heterozygosity of 0.001 for SNPs. We use the standard
expression for the probability density of the number of variable sites in the infinite sites
model and the allele frequency prior given that a site is variable (see e.g. Wakeley et al. 22).
The purpose of the dynamic programming is to calculate the probability that given k
previous sites, the next variable site k+1 is a site with frequency count at most fmax, and that
the derived allele is present only on chromosomes of affected individuals; conditional on
this event, we calculate the probability that such a mutation at site k+1 is present on the
chromosomes of affected individuals that had no previous mutations (up to site k) satisfying
the same criteria. Weighted by the probability of observing k variable sites, this then
provides an estimate of the probability that all chromosomes of affected individuals carry at
least one mutation of frequency at most fmax and not present in controls.
Zebrafish experiments
Zebrafish husbandry—General maintenance, collection, and staging of the wild type and
transgenic Tg(cd41:EGFP) zebrafish were carried out according to the Zebrafish Book23.
Embryos were maintained in egg water (60 mg/L Red Sea salts) at 28°C until the
appropriate stage.
O-Dianisidine staining—O-Dianisidine staining for haemoglobin was performed as
previously described24. In brief, unfixed embryos were dechorionated and stained for 10
minutes in the dark, with a solution consisting of o-Dianisidine (0.7 mg/ml), 0.01 M sodium
acetate (pH 4.5), 0.65% hydrogen peroxide and 45% (vol/vol) ethanol. Photomicrographs
were taken with a Zeiss camera AxioCam HRC attached to a LeicaMZ16 FA dissecting
microscope.
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Nbeal2 antisense oligonucleotides—Morpholinos (MO) targeting zebrafish nbeal2 atg
(5′-TCGAAGCCATTCTCCCTCGCCCTTC-3′) and standard control MO (5′-
CCTCTTACCTCAGTTACAATTTATA-3′) were obtained from GeneTools LLC
(Philomath, Oregon). The MO were resuspended in sterile water and approximately 0.8 nl
was injected in zebrafish embryos, at the one cell stage. For both nbeal2 atg MO and the
standard control MO a concentration of 1 μg/μl was used.
Expression of BEACH domain containing genes in tissues
Transcript profiling of blood cells and blood cell precursors—Data about
transcript levels of in the above cells were extracted from a compendium of expression data
sets generated by the Bloodomics Consortium and which in part have been released via
Array Express at the European Bioinformatics Institute (www.ebi.ac.uk). Two main datasets
have been used in this study: i) the HaemAtlas25 which encompasses the results of whole
genome expression (WGE) studies performed with RNA samples from the eight main blood
cell types, including megakaryocytes (MKs) and erythroblasts (EBs) and ii) the WGE results
obtained with the RNA samples from CD34+ haematopoietic stem cells (HSCs) and from a
study of paired HSC cultures that were differentiated towards MKs and EBs. Cells were
harvested during the 10-day culture at five time points in time (days 3, 5, 7, 9 and 10).
HaemAtlas25: The purification of blood cells is described in25. In short, RNA was isolated
from the six main blood cell types (CD4+ Th (CD4, n=7) and CD8+ Tc lymphocytes (CD8,
n=7), CD14+ monocytes (CD14, n=7), CD19+ B lymphocytes (CD19, n=7), CD56+ natural
killer (NK) cells (CD56, n=7) and CD66b+ granulocytes (CD66, n=7) obtained from seven
healthy blood donors from the Cambridge BioResource and from MKs and EBs. The latter
two cells were obtained by cultures of cord blood-derived CD34+ HSCs. MKs were obtained
by cultures for 7 days in a medium supplemented with human recombinant thrombopoietin
(THPO) and interleukin-1ß (IL1B) and the latter by cultures for 10 days in the presence of
erythropoietin (EPO), interleukin-3 (IL3) and stem cell factor (SCF). To ensure high level
purity preparations of both MKs and EBs, cells were flow-sorted using monoclonal
antibodies against CD markers: MKs were positive for CD41 and negative for CD34; EBs
were negative for CD41 and positive for CD235a. RNA was prepared from two sets of four
cell preparations each.
Platelet Whole-Genome Expression data: Platelet RNA was isolated using a Trizol
standard protocol. Total RNA was quantified using the NanoDrop (Labtech International)
and quality-checked using the 2100 Bioanalyzer (Agilent Technologies). Standard protocols
were applied to generate biotinylated cRNA and hybridize to Illumina BeadChips
HumanWG-6 v2. Then, arrays were washed and scanned. All experimental procedures were
carried out according to the manufacturer’s protocol.
Time-course study of MK and EB cultures: To capture changes in transcript levels over
time during the proliferation and differentiation of HSCs towards MKs and EBs paired
cultures were generated as described above using CD34+ HSCs from three cord blood
donations. Umbilical cord blood of three healthy newborns was collected into cord blood
collections bags (MacoPharma, Mouvaux, France) with parental informed consent. CD34+
HSCs were prepared as in26 and 92-98% pure CD34+ HSCs were in vitro cultured (1×105/
ml) for 10 days in serum-free media (CellGro-SCGM, Cellgenix, France) supplemented with
50 ng/ml THPO (CellGenix, France) and 10 ng/ml IL1B (Miltenyi Biotech, Surrey, UK) to
differentiate into MKs. EBs were in vitro derived from HSCs (5×103/ml) in the presence of
6 U/ml EPO (R&D Systems, Abingdon, UK), 10 ng/ml IL3 (Miltenyi Biotech, Surrey, UK)
and 100 ng/ml SCF (R&D Systems, Abingdon, UK). MKs and EBs were harvested at day 3,
5, 7, 9 and 10 as described in26 and transferred for RNA isolation into a 5 ml tube,
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centrifuged at 500 x g for 10 min at RT, resuspended in Trizol (Invitrogen, Paisley, UK) and
stored at −80°C. Total RNA was isolated according to manufacturer’s instructions. The
following murine monoclonal antibodies were used for phenotyping of both lineages at day
10: Fluorescein isothiocyanate (FITC) IgG1 isotype control, Phycoerythrin (PE) IgG1
isotype control, Allophycocyanin (APC) IgG1 isotype control, PE-Cy5 IgG1 isotype control
and Pacific Blue (PB) isotype control (BD Bioscience Pharmingen™, Becton Dickinson,
Oxford, UK), anti-CD11c V450, anti-CD13 APC, anti-CD14 PB, anti-CD15 V450, anti-
CD33 FITC (BD Bioscience Pharmingen™), anti-CD34 PE (Beckman Coulter, High
Wycombe, UK), anti-CD36 PE, anti-CD41a APC, anti-CD42a FITC, anti-CD235a FITC
and anti-CD66c PE (BD Bioscience Pharmingen™). For phenotyping of cells at all other
days anti-CD34 PE and anti-CD41a APC, anti-CD42a FITC and anti-CD235a FITC with
matching isotype controls were used. In addition, a ploidy stain of the MKs was performed
at each day of harvest as described in26. In brief, cells were stained with anti-CD41a APC
and with matched isotype control and incubated at 37°C for 30 min in 500 μl PBE buffer
containing 0.1% (v/v) Tween 20, RNAse A (0.1 mg/ml) and propidium iodide (0.05 mg/ml,
Sigma-Aldrich, Dorset, UK). Samples were analysed using a 9-colour Cyan-ADP flow
cytometer running Summit software version 4.3.02 (Beckman Coulter).
Sequencing of megakaryocyte RNA
Total RNA was prepared from MKs that were obtained using the culture protocol described
above and extraction of RNA was according to the Trizol method (Invitrogen, Paisley, UK).
The RNA pellet was resuspended in nuclease-free water (Applied Biosystems, Warrington,
UK) and analysis by Agilent Bioanalyser 2100 (Agilent, Waldbronn, Germany) gave a RNA
integrity number (RIN)27 number of 8.4. Following DNAse treatment (Turbo DNA-Free,
Applied Biosystems), 5 μg of total RNA was applied to the mRNA Sequencing kit
(Illumina) following the manufacturer’s instructions, except that PCR was performed before
gel extraction of a band range of 300-450 bp, to obtain the purified library. This was
quantified by qPCR followed by paired-end sequencing by GAII analyser (Illumina).
Paired-end 76 bp RNA-seq reads were obtained for the in-vitro derived MK samples
(above). We sequenced one lane on the Illumina GAIIx and obtained 40,539,150 reads. The
data were initially assessed using the FASTX-Toolkit version 0.0.1328 and the ShortRead29
package from version 2.7 of the Bioconductor project. Reads were then aligned to the
February 2009 Homo sapiens high coverage assembly (Hg19) using TopHat v1.2.030.
Default parameters allow for up to 40 alignments per read with a maximum of 2
mismatches. The alignments here were produced using more stringent parameters where
only a single unique alignment was allowed per read. We used BEDTools31 to calculate the
read coverage from the alignments, and visualized the results on the IGV browser32 using
the Ensembl annotation.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Mutations in NBEAL2 in Gray Platelet Syndrome cases. (a) Electron micrographs showing
discoid normal platelets with abundant α-granules in comparison with a selection of
platelets from Gray Platelet Syndrome (GPS) cases A.II.3 and B.II.3. The GPS platelets
have heterogeneous shapes and characteristically lack α-granules. They normally contain
mitochondria (Mi); morphological abnormalities include the presence of membrane
complexes (MC), occasional large vacuoles (V) and an overdeveloped Open Canalicular
System (OCS). Bars represent 1μm. (b) Novel variants in neurobeachin-like 2 (NBEAL2) in
4 whole-exome sequenced index cases (A-D, Supplementary Table 1) explain GPS.
Heterozygous mutations are shown in black and homozygous ones in red. InterPro protein
domains are shown as colored bars above the transcript, where blue indicates the
characteristic BEACH domain. Sequencing reads showed that the splice and S2268L
variants occurred on the same chromosome. (c) Silencing of nbeal2 in zebrafish. To assess
the function of nbeal2 in thrombopoiesis we investigated cd41 expression in caudal
haematopoietic tissue (CHT) of Tg(cd41:EGFP) transgenic embryos, at 3 days post-
fertilisation (dpf). nbeal2 morpholino (MO) knockdown resulted in a complete abrogation of
thrombocytes (the zebrafish equivalent of human platelets) when compared to control (white
arrowhead). White bars represent ~100μm. (d) Whole mount o-Dianisidine staining for
mature erythrocytes at 3 dpf showed that the total number of mature erythrocytes was not
affected in nbeal2-depleted embryos when compared to control (white arrow). (e) nbeal2
MO-injected embryos showed normal morphological development and vigorous circulation
at 3 dpf, similar to control embryos. However, 41% of nbeal2 depleted embryos (N=78), and
no control embryos (N=78) developed spontaneous bleedings visible within the tail of the
embryo (left column). These spontaneous bleedings were confirmed with o-Dianisidine
staining (right column, white arrows indicate the location of bleeding).
Albers et al. Page 10
Nat Genet. Author manuscript; available in PMC 2012 August 28.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Albers et al. Page 11
Ta
bl
e 
1
N
ov
el
 v
ar
ia
nt
s i
n 
N
BE
A
L2
.
 
Ch
ro
m
os
om
al
 c
oo
rd
in
at
es
 a
re
 g
iv
en
 re
la
tiv
e 
to
 b
ui
ld
 N
CB
I3
7 
of
 th
e 
re
fe
re
nc
e 
ge
no
m
e.
 F
un
ct
io
na
l c
on
se
qu
en
ce
s w
er
e 
pr
ed
ic
te
d 
fro
m
 th
e 
CC
D
S 
tra
ns
cr
ip
t, 
w
hi
ch
 w
as
 c
on
fir
m
ed
by
 th
e 
se
qu
en
ci
ng
 o
f M
K
 R
N
A
 (s
ee
 Su
pp
lem
en
tar
y N
ote
), a
nd
 w
ere
 ei
the
r n
on
-sy
no
ny
mo
us
 (n
s) 
or 
dis
rup
tin
g a
 sp
lic
e s
ite
. S
IF
T 
an
d P
oly
ph
en
 w
ere
 us
ed
 to
 pr
ed
ict
 de
let
eri
ou
s i
mp
ac
t o
f t
he
 m
uta
tio
ns
.
Co
ns
er
va
tio
n 
is 
de
fin
ed
 a
s t
he
 n
um
be
r o
f s
pe
ci
es
 w
he
re
 th
e 
re
sid
ue
 w
as
 id
en
tic
al
 to
 th
at
 in
 h
um
an
 o
ut
 o
f t
he
 n
um
be
r o
f s
pe
ci
es
 th
at
 h
ad
 a
 p
ro
te
in
 a
lig
nm
en
t a
t t
he
 p
os
iti
on
 o
f t
he
 m
ut
at
io
n,
 u
sin
g 
a 
to
ta
l o
f 3
7
sp
ec
ie
s i
nc
lu
di
ng
 p
rim
at
es
, p
la
ce
nt
al
 m
am
m
al
s a
nd
 v
er
te
br
at
es
. T
he
 la
st 
fo
ur
 c
ol
um
ns
 sh
ow
 th
e 
ge
no
ty
pe
 o
f t
he
 fo
ur
 c
as
es
, w
he
re
 ‘r
ef
’, 
‘h
et
’ a
nd
 ‘h
om
-a
lt’
 in
di
ca
te
s a
 h
om
oz
yg
ot
e 
fo
r t
he
 re
fe
re
nc
e 
al
le
le
, a
he
te
ro
zy
go
te
 a
nd
 a
 h
om
oz
yg
ot
e 
fo
r t
he
 a
lte
rn
at
e 
no
n-
re
fe
re
nc
e 
al
le
le
, r
es
pe
ct
iv
el
y.
Po
sit
io
n
V
ar
ia
nt
SI
FT
Po
ly
ph
en
Ex
on
Ty
pe
A
A
 c
ha
ng
e
C
on
se
rv
at
io
n
A
B
C
D
ch
r3
:4
70
30
44
7
A
/G
To
le
ra
te
d
B
en
ig
n
3
n
s
I8
6V
23
/2
7
re
f
re
f
re
f
he
t
ch
r3
:4
70
35
47
6
T/
C
D
am
ag
in
g
Po
ss
ib
ly
 d
am
ag
in
g
11
n
s
L3
88
P
33
/3
4
ho
m
-a
lt
re
f
re
f
re
f
ch
r3
:4
70
37
23
3
A
/T
D
am
ag
in
g
Po
ss
ib
ly
 d
am
ag
in
g
14
n
s
E6
43
V
31
/3
1
re
f
re
f
he
t
re
f
ch
r3
:4
70
37
43
4
A
/T
D
am
ag
in
g
B
en
ig
n
15
n
s
I6
82
F
30
/3
2
re
f
ho
m
-a
lt
re
f
re
f
ch
r3
:4
70
46
46
6
C/
T
D
am
ag
in
g
Pr
ob
ab
ly
 d
am
ag
in
g
39
n
s
P2
10
0L
29
/2
9
re
f
re
f
he
t
re
f
ch
r3
:4
70
47
43
4
A
/A
G
G
A
G
TA
G
N
A
N
A
42
-4
3
sp
lic
e 
sit
e
In
tro
ni
c
31
/3
1
re
f
re
f
re
f
he
t
ch
r3
:4
70
47
44
0
C/
T
D
am
ag
in
g
Po
ss
ib
ly
 d
am
ag
in
g
43
n
s
S2
26
9L
31
/3
1
re
f
re
f
re
f
he
t
ch
r3
:4
70
49
61
5
G
/A
To
le
ra
te
d
B
en
ig
n
50
n
s
G
25
53
E
6/
33
re
f
re
f
re
f
he
t
Nat Genet. Author manuscript; available in PMC 2012 August 28.
